Home

Michael Zinda

CIK 1815366 · EVP, CHIEF SCIENTIFIC OFFICER · last filed 2025-03-14

Michael Zinda is an EVP, CHIEF SCIENTIFIC OFFICER who has filed 22 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider sold $6.4K of RPTX on Mar 14, 2025. Across all open-market trades the lifetime net is −$6.7M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

22

Lifetime Open-Market Net

-$6.67M

Filer Profile

Reported Address
C/O REPARE THERAPEUTICS INC.
7210 FREDERICK-BANTING, SUITE 100
ST-LAURENT, A8 H4S 2A1
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Repare Therapeutics Inc. (RPTX) Delisted EVP, CHIEF SCIENTIFIC OFFICER 80,297 $2.65 $212.8K -$6.67M 20 2025-03-14

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-03-14 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −5,611 -$6.4K EDGAR
2025-03-06 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) +14,000 $0 EDGAR
2024-04-01 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −860 -$4.0K EDGAR
2024-03-27 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −1,350 -$6.3K EDGAR
2024-03-25 Repare Therapeutics Inc. (RPTX) Delisted Notice (144) −2,210 -$10.8K EDGAR
2024-03-04 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) +14,000 $0 EDGAR
2023-06-09 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −3,535 -$42.6K EDGAR
2023-06-07 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −1,200 -$14.4K EDGAR
2023-06-06 Repare Therapeutics Inc. (RPTX) Delisted Notice (144) −10,473 -$123.1K EDGAR
2023-02-01 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) +24,550 $0 EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.